A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma (CL-PTL-130)

Administered By

Awarded By

Contributors

Start/End

  • October 4, 2019 - October 31, 2023